ClinicalTrials.gg
RecruitingNCT01587300Updated Mar 23, 2026

Neuroblastoma Biology Study

An observational study in Neuroblastoma, sponsored by New Approaches to Neuroblastoma Therapy Consortium. Recruiting at 17 sites in 2 countries. Open to participants aged 31 Days to 99 Years. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by New Approaches to Neuroblastoma Therapy Consortium · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
1,000
Ages
31 Days to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 24 studies in Neuroblastoma by New Approaches to Neuroblastoma Therapy Consortium — 3 open to participants now, 6 under way, none of them phase 3. Neuroblastoma · New Approaches to Neuroblastoma Therapy Consortium.

Started
2011
the only one that year
Observational
2 of 24
1 open now
Registered
13th of 24
by date

Among the 24 studies in Neuroblastoma by New Approaches to Neuroblastoma Therapy Consortium, this one is the only one that started in 2011, is one of 2 observational ones, and was the 13th registered.

Neuroblastoma

676 studies on the registry are indexed under Neuroblastoma; 127 are open to participants now.

Browse Neuroblastoma studies →

Open to participants now

3 of the 24 studies in Neuroblastoma by New Approaches to Neuroblastoma Therapy Consortium are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 104 Neuroblastoma studies recruiting now, 25 (24%) set no upper age limit and 74 (71%) stop at 75 or younger; 101 take children under 18; 3 take healthy volunteers.

This study: 31 Days to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Neuroblastoma by New Approaches to Neuroblastoma Therapy Consortium, or all of them as a file.
02

Study summary

Medical scientists want to find better ways to treat neuroblastoma and to find ways to prevent the tumor from growing back. To do this, they need more information about the characteristics of neuroblastoma cells. Therefore, they want to study samples of neuroblastoma tissues and neuroblastoma and normal cells in the blood and bone marrow that may be related to the growth of neuroblastoma cells. Doctors and other medical scientists also want to find better ways to detect and measure neuroblastoma to improve the ability to follow the response of tumor cells to therapy.

Read the detailed description

The purposes of this study are:

To establish a storage place or bank of samples of blood, bone marrow, and/or tumor, and molecular components isolated from these samples from children with neuroblastoma. The stored specimens will be shared with laboratory researchers studying high risk neuroblastoma.

To collect clinical data (such as treatments received, date of diagnosis, tumor stage, etc) and radiology scans to provide this information as needed for the laboratory studies to be done on the specimens.

To obtain neuroblastoma tumor cells from tumor tissue, bone marrow, and/or blood to use to start cell lines, or tumor cells that will keep growing in the laboratory. These cell lines will be shared with laboratory researchers studying high risk neuroblastoma.

03

Conditions studied

  • Neuroblastoma

Browse trials for

04

Who can participate

Ages eligible
31 Days to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Neuroblastoma patients from various NANT sites.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must be greater than or 31 days of age.
  • Patients must have had a diagnosis of high risk neuroblastoma either by histological verification of neuroblastoma and/or demonstration of tumor cells in the bone marrow with increased urinary catecholamines.
  • All patients with or recurrent high risk neuroblastoma at NANT institutions are eligible regardless of disease status (including no measurable or evaluable tumor) as long as they undergo a disease evaluation and appropriate samples are submitted.
  • Additionally, all patients with high risk neuroblastoma without relapse treated at a NANT institution are eligible if undergoing a disease evaluation, as long as Children's Oncology Group specimens are prioritized.

Exclusion criteria

Exclusion Criteria:

  • There are no exclusion criteria on this study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Biospecimen retention
Samples with dna
06

Study locations

13 of 17 sites recruiting
  • Children's Hospital Los Angeles
    Los Angeles, California 90027-0700, United States
    Recruiting
    • Araz Marachelian, MD · Contact
  • Lucille Salter Packer Children's Hospital, Stanford University
    Palo Alto, California 94305, United States
    Completed

    Not enrolling at this site.

  • UCSF Helen Diller Family Comprehensive Cancer Center
    San Francisco, California 94115, United States
    Recruiting
    • Kieuhoa Vo, MD · Contact
  • Children Hospital of Colorado
    Aurora, Colorado 80045, United States
    Recruiting
    • Margaret Macy, MD · Contact
  • AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus
    Atlanta, Georgia 30322, United States
    Recruiting
    • Kelly Goldsmith, MD · Contact
  • University of Chicago, Comer Children's Hospital
    Chicago, Illinois 60637, United States
    Recruiting
    • Ami Desai, MD · Contact
  • Children's Hospital Boston
    Boston, Massachusetts 02115, United States
    Recruiting
    • Suzanne Shusterman, MD · Contact
  • C.S Mott Children's Hospital
    Ann Arbor, Michigan 48109, United States
    Recruiting
    • Rajen Mody, MD · Contact
  • University of North Carolina
    Chapel Hill, North Carolina 27599, United States
    Completed

    Not enrolling at this site.

  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229-3039, United States
    Recruiting
    • Katherine Somers, MD · Contact
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
    Recruiting
    • Keri Streby, MD · Contact
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104-4318, United States
    Recruiting
    • Yael Mosse, MD · Contact
  • St. Jude Children's Research Hospital
    Memphis, Tennessee 38105, United States
    Not yet recruiting
    • Sara Federico, MD · Contact
  • University of Texas Southwestern
    Dallas, Texas 75235, United States
    Not yet recruiting
    • Tanya Watt, MD · Contact
  • Cook Children's Medical Center - Fort Worth
    Fort Worth, Texas 76104, United States
    Recruiting
    • Chelsee Greer, DO · Contact
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
    Recruiting
    • Mark Fluchel, MD · Contact
  • Hospital for Sick Children
    Toronto, Ontario M5G 1X8, Canada
    Recruiting
    • Daniel Morgenstern, MD · Contact
07

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of Dec 2099 and a completion of Dec 2099. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2012
First posted
Apr 30, 2012
Start
Jul 2011
Primary completionEst.
Dec 2099
CompletionEst.
Dec 2099
Last update
Mar 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT01587300
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Responsible party
Sponsor
First posted
Apr 30, 2012
Start date
Jul 2011
Primary completion
Dec 2099 (estimated)
Completion
Dec 2099 (estimated)
Last update
Mar 23, 2026

Study contacts

Araz Marachelian, MD
Contact
amarachelian@chla.usc.edu
323-361-5687
Shahab Asgharzadeh, MD
study chair · Children's Hospital Los Angeles

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion